Predictive value of serum apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk: Population-based cohort study

被引:18
作者
Onat, Altan [1 ]
Can, Gunay [2 ]
Cicek, Gokhan [3 ]
Ayhan, Erkan [3 ]
Dogan, Yuksel [4 ]
机构
[1] Istanbul Univ, Dept Cardiol, Cerrahpasa Med Fac, Istanbul, Turkey
[2] Istanbul Univ, Dept Publ Hlth, Cerrahpasa Med Fac, Istanbul, Turkey
[3] S Ersek Cardiovasc Surg Ctr, Istanbul, Turkey
[4] Bakirkoy Sadi Konuk Educ Hosp, Istanbul, Turkey
关键词
Coronary heart disease; Diabetes type-2; Insulin resistance; LDL particle number and size; Triglycerides; LOW-DENSITY-LIPOPROTEIN; INSULIN-RESISTANCE ATHEROSCLEROSIS; NUCLEAR-MAGNETIC-RESONANCE; HORMONE-BINDING GLOBULIN; METABOLIC SYNDROME; ABDOMINAL OBESITY; CARDIOVASCULAR-DISEASE; CORONARY-DISEASE; HEART-DISEASE; MEN;
D O I
10.1016/j.clinbiochem.2010.08.027
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: We determined the independent predictive value of serum apolipoprotein (apo) B/LDL-cholesterol ratio for the risk of diabetes, metabolic syndrome (MetS) and coronary heart disease (CHD). Design and methods: Prediction of incident cases was assessed in 2466 adults at 7 years follow-up. Results: ApoB/LDL ratio was independently associated log-linearly with waist circumference, and, only in men, with HDL-cholesterol in a multivariable regression model. Positive partial correlations existed with fasting insulin, fibrinogen and apo A-I and, only in women, with CRP. Cox regression analyses revealed the two highest apoB/LDL quartiles to be significant determinants of diabetes, at 2-fold RRs, independently of waist circumference, fasting glucose and other confounders. However, apoB/LDL quartiles were not independently associated with CHD in either gender. Only the highest apoB/LDL quartile was associated (RR 1.46) with the development of MetS. Serum apoB/LDL-cholesterol ratio, determined by insulin resistance and in women additionally by pro-inflammatory state, is of independent predictive value for incident diabetes and weakly for MetS, but not for CHD. (C) 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1381 / 1386
页数:6
相关论文
共 31 条
[1]  
[Anonymous], 1982, CARDIOVASCULAR SURVE
[2]  
[Anonymous], 2001, JAMA, V285, P2486
[3]   ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].
AUSTIN, MA ;
KING, MC ;
VRANIZAN, KM ;
KRAUSS, RM .
CIRCULATION, 1990, 82 (02) :495-506
[4]   Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein [J].
Backes, JM ;
Gibson, CA .
ANNALS OF PHARMACOTHERAPY, 2005, 39 (03) :523-526
[5]   Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance [J].
Garvey, WT ;
Kwon, S ;
Zheng, D ;
Shaughnessy, S ;
Wallace, P ;
Hutto, A ;
Pugh, K ;
Jenkins, AJ ;
Klein, RL ;
Liao, YL .
DIABETES, 2003, 52 (02) :453-462
[6]  
Genuth S, 2003, DIABETES CARE, V26, P3160
[7]   Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: Relationship to multiple lipoprotein phenotype [J].
Georgieva, AM ;
van Greevenbroek, MMJ ;
Krauss, RM ;
Brouwers, MCGJ ;
Vermeulen, VMMJ ;
Robertus-Teunissen, MG ;
van der Kallen, CJH ;
de Bruin, TWA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (04) :744-749
[8]   Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study [J].
Goff, DC ;
D'Agostino, RB ;
Haffner, SM ;
Otvos, JD .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (02) :264-270
[9]  
Grundy SM, 2004, CIRCULATION, V109, P433, DOI [10.1161/01.CIR.0000111245.75752.C6, 10.1161/01.CIR.0000112379.88385.67]
[10]   Low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoprotein in normoglycemic men [J].
Haffner, SM ;
Laakso, M ;
Miettinen, H ;
Mykkanen, L ;
Karhapaa, P ;
Rainwater, DL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) :3697-3701